Well, it didn’t take long for Sanofi to follow Eli Lilly and Novo Nordisk to cut its insulin prices. Yesterday it announced starting next year, Lantus, its most popular insulin will.come down 78%, with a monthly cap of $ 35 for people with private insurance. It’s also lowering the price of its short-acting insulin, Apridra, 70%. … Continue reading Sanofi is the last to lower insulin prices starting January 1, 2024
Diabetes Stories